Personalis Total Long Term Liabilities 2018-2024 | PSNL
Personalis total long term liabilities from 2018 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Personalis Annual Total Long Term Liabilities (Millions of US $) |
2023 |
$48 |
2022 |
$41 |
2021 |
$55 |
2020 |
$9 |
2019 |
$1 |
2018 |
$90 |
2017 |
$ |
Personalis Quarterly Total Long Term Liabilities (Millions of US $) |
2024-09-30 |
$37 |
2024-06-30 |
$39 |
2024-03-31 |
$43 |
2023-12-31 |
$48 |
2023-09-30 |
$43 |
2023-06-30 |
$44 |
2023-03-31 |
$44 |
2022-12-31 |
$41 |
2022-09-30 |
$42 |
2022-06-30 |
$52 |
2022-03-31 |
$54 |
2021-12-31 |
$55 |
2021-09-30 |
$55 |
2021-06-30 |
$11 |
2021-03-31 |
$9 |
2020-12-31 |
$9 |
2020-09-30 |
$9 |
2020-06-30 |
$9 |
2020-03-31 |
$1 |
2019-12-31 |
$1 |
2019-09-30 |
$1 |
2019-06-30 |
$18 |
2019-03-31 |
|
2018-12-31 |
|
2018-09-30 |
|
2018-06-30 |
|
2017-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.239B |
$0.073B |
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|